Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt released the following statement on the House Energy and Commerce Health Subcommittee’s hearing Combating the Opioid Crisis: Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it has acquired global development and marketing rights from Prayog Labs LLC to bring to market a fast-acting Meloxicam as a proposed non-narcotic analgesic. Read More »

Just announced that John Renger, Ph.D., has been appointed Vice President, Head of Research & Development and Regulatory Affairs. He will be based in Stamford, Connecticut and report directly to President and CEO Craig Landau, MD. Read More »

As the independent drugstore lobby descends on Capitol Hill this week to push for costly new government health mandates, the Pharmaceutical Care Management Association (PCMA) continues to highlight how pharmacy benefit managers (PBMs) reduce prescription drug costs and improve benefits for consumers, employers, unions, and public programs. Read More »

ASHP, in collaboration with the Pediatric Pharmacy Advocacy Group (PPAG), today published updated national guidelines outlining best practices for pediatric pharmacy care in hospitals and health systems. Read More »

Afinitor DISPERZ (everolimus) is first adjunctive treatment approved in US for patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Read More »

One of the world's leading pharmaceutical companies, and Mapi Pharma Ltd., a fully integrated, clinical late stage biopharmaceutical company, today announced that the two companies will partner on the development and commercialization of GA Depot, a long-acting Glatiramer Acetate product. Mylan is acquiring global marketing rights to the product. Read More »

Report from Orexo AB’s annual general meeting Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to Humira® (adalimumab) developed by Fujifilm Kyowa Kirin Biologics. Through the partnership agreement, Mylan will leverage its regulatory platform to seek approval and commercialize the product in Europe. Read More »

Imagine having a chronic disease that affects almost every organ in your body and can lead to intense, debilitating pain episodes that often send you to the ER.1,2 What’s more, there are generally no warning signs, making it difficult to not only plan ahead for special events, but to keep up with the day-to-day activities most people take for granted. Too often, this is a recurring cycle for people with sickle cell disease (SCD). Read More »

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the pricing of a private offering of $1.5 billion aggregate principal amount of senior notes on March 28, 2018 Read More »

Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets. Read More »

The annual Harvey A.K. Whitney Lecture Award recognizes individuals who have made outstanding contributions to health-system pharmacy. The award is considered to be the highest honor in the profession. Read More »

AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), announced notification by the U.S. Food and Drug Administration (FDA) that it requires extended time to review additional information regarding the results of liver function tests provided by AbbVie in connection with its New Drug Application (NDA) for elagolix in endometriosis-associated pain. The Prescription Drug User Fee Act (PDUFA) date has been extended three months to Q3 2018. Read More »

Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that its REDUCE-IT cardiovascular outcomes study of Vascepa® (icosapent ethyl) is estimated to have reached the onset of the targeted 1,612 primary major adverse cardiovascular events (MACE) specified in the study design. Read More »

Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Read More »

Aetna’s continuing work on helping combat the opioid epidemic includes a study suggesting the strength of the drug might not be the best predictor of misuse. Read More »

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-COMPARE clinical trial showing that after 12 weeks, upadacitinib (15 mg, once-daily) met the primary endpoints of ACR20a and clinical remissionb versus placebo.1 All ranked secondary endpoints were also achieved versus either placebo or adalimumab (40 mg every other week). Read More »

ASHP’s virtual House of Delegates recently approved professional policies on gene therapy, unit dose packaging availability, and drug dosing in conditions that modify pharmacokinetics or pharmacodynamics, among other topics. Following discussion in the House of Delegates community on ASHP Connect, delegates voted online during the week of March 16–23. Read More »

Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced an update to its revenue guidance for the first quarter of 2018, reiteration of full year revenue guidance, further progress towards completing its potential landmark cardiovascular outcomes study, REDUCE-IT, and initiation of previously announced Vascepa® promotion initiatives. Read More »